Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Ketosis-prone Diabetes and Hypogonadism: A New Clinical Association to be Aware of ?

Author(s): Andrea Graziani, Riccardo Maria Pollis*, Benedetta Maria Bonora, Carla Scaroni and Chiara Sabbadin

Volume 23, Issue 12, 2023

Published on: 24 July, 2023

Page: [1552 - 1556] Pages: 5

DOI: 10.2174/1871530323666230621114503

Price: $65

Abstract

Background: Ketosis-prone diabetes (KPD) is an emerging entity, sharing features of both type 1 diabetes mellitus and type 2 diabetes mellitus. Patients with KPD usually present with diabetic ketoacidosis without the classic phenotype of autoimmune type 1 diabetes. In most cases, they are Afro-American adults, who require insulin therapy for the management of acute decompensation, then usually encountering insulin-free remission for prolonged periods of time with diet or with non-insulin agents. Meanwhile, hypogonadism is a known condition that could be associated with higher risk of developing both type 1 and type 2 diabetes and could be a risk factor for decompensated diabetes. The association of KPD and hypogonadism is reported for the first time in literature.

Case Presentation: Here we report two peculiar cases of young African patients, affected by KPD and hypergonadotropic hypogonadism, respectively Klinefelter’s syndrome and primary ovarian failure. Both patients were treated promptly for the ketoacidosis with intravenous fluids combined with continuous insulin infusion, and then switched to subcutaneous regimen. After the correct clinical evaluation, oral antidiabetic drugs were added.

Conclusion: KPD remains an under-recognized and under-diagnosed type of diabetes. As hypogonadism is strongly linked to dysmetabolic disorders, the evaluation of sex hormones should be performed at the onset of diabetes. Further studies should investigate the hypothalamic-pituitary-gonadal axis and its role in the development of KDP and its manifestations and complications.

« Previous Next »
Graphical Abstract

[1]
Balasubramanyam, A. SYNDROMES OF KETOSIS-PRONE DIABETES. Trans. Am. Clin. Climatol. Assoc., 2019, 130, 145-155.
[PMID: 31516178]
[2]
Mauvais-Jarvis, F.; Sobngwi, E.; Porcher, R.; Riveline, J.P.; Kevorkian, J.P.; Vaisse, C.; Charpentier, G.; Guillausseau, P.J.; Vexiau, P.; Gautier, J.F. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: Clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes, 2004, 53(3), 645-653.
[http://dx.doi.org/10.2337/diabetes.53.3.645] [PMID: 14988248]
[3]
Lebovitz, H.E.; Banerji, M.A. Ketosis-prone diabetes (flatbush diabetes): an emerging worldwide clinically important entity. Curr. Diab. Rep., 2018, 18(11), 120.
[http://dx.doi.org/10.1007/s11892-018-1075-4] [PMID: 30280274]
[4]
Oli, J.M. Remittant diabetes mellitus in Nigeria. Trop. Geogr. Med., 1978, 30(1), 57-62.
[PMID: 675828]
[5]
Tan, H.; Wang, C.; Yu, Y. Ketosis-prone diabetes mellitus in an obese adolescent: A case report. Medicine, 2019, 98(25), e16076.
[http://dx.doi.org/10.1097/MD.0000000000016076]
[6]
Gaba, R.; Mehta, P.; Balasubramanyam, A. Evaluation and management of ketosis-prone diabetes. Expert Rev. Endocrinol. Metab., 2019, 14(1), 43-48.
[http://dx.doi.org/10.1080/17446651.2019.1561270]
[7]
Banerji, M.A.; Chaiken, R.L.; Huey, H.; Tuomi, T.; Norin, A.J.; Mackay, I.R.; Rowley, M.J.; Zimmet, P.Z.; Lebovitz, H.E. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4.Flatbush diabetes. Diabetes, 1994, 43(6), 741-745.
[8]
Umpierrez, G.E.; Smiley, D.; Kitabchi, A.E. Narrative review: Ketosis-prone type 2 diabetes mellitus. Ann. Intern. Med., 2006, 144(5), 350-357.
[http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00011] [PMID: 16520476]
[9]
Gaba, R.; Balasubramanyam, A. Covid-19: A new cause of “provoked” A-β+ Ketosis-Prone Diabetes. J. Diabetes Complications, 2022, 36(4), 108147.
[10]
Lefèbvre, P. Ketosis-prone atypical diabetes: Glucagon is there, too. Diabetes Care, 2013, 36(1), 8-10.
[11]
Yang, D.; Patel, S.; Szlachcic, W.J.; Chmielowiec, J.; Scaduto, D.; Putluri, N.; Sreekumar, A.; Suliburk, J.; Metzker, M.; Balasubramanyam, A.; Borowiak, M. Pancreatic differentiation of stem cells reveals pathogenesis of a syndrome of ketosis-prone diabetes. Diabetes, 2021, 70(10), 2419-10.
[http://dx.doi.org/10.2337/db20-1293]
[12]
Álvarez-Aldana, D. Improving ketosis-prone type 2 diabetes diagnosis in africa. MEDICC Rev., 2021, 23(3-4), 61-62.
[http://dx.doi.org/10.37757/MR2021.V23.N3.11] [PMID: 34516538]
[13]
Zitzmann, M.; Aksglaede, L.; Corona, G.; Isidori, A.M.; Juul, A. European academy of andrology guidelines on Klinefelter Syndrome Endorsing Organization: European Society of Endocrinology. Andrology, 2021, 9(1), 145-167.
[14]
Sakurai, T.; Iizuka, K.; Kato, T.; Takeda, J. Type 1 Diabetes Mellitus and Klinefelter Syndrome. Intern. Med., 2019, 58(2), 259-262.
[15]
O’Connor, M.J.; Snyder, E.A.; Hayes, F.J. Klinefelter yyndrome and diabetes. Curr. Diab. Rep., 2019, 19(9), 71.
[http://dx.doi.org/10.1007/s11892-019-1197-3]
[16]
Szeliga, A.; Calik-Ksepka, A.; Maciejewska-Jeske, M.; Grymowicz, M.; Smolarczyk, K.; Kostrzak, A.; Smolarczyk, R.; Rudnicka, E.; Meczekalski, B. Autoimmune diseases in patients with premature ovarian insufficiency-our current state of knowledge. Int. J. Mol. Sci., 2021, 22(5), 2594.
[http://dx.doi.org/10.3390/ijms22052594] [PMID: 33807517]
[17]
Kulaksizoglu, M.; Ipekci, S.H.; Kebapcilar, L.; Kebapcilar, A.G.; Korkmaz, H.; Akyurek, F.; Baldane, S.; Gonen, M.S. Risk factors for diabetes mellitus in women with primary ovarian insufficiency. Biol. Trace Elem. Res., 2013, 154(3), 313-320.
[http://dx.doi.org/10.1007/s12011-013-9738-0]
[18]
Maggio, M.; Basaria, S. Welcoming low testosterone as a cardiovascular risk factor. Int. J. Impot. Res., 2009, 21(4), 261-264.
[http://dx.doi.org/10.1038/ijir.2009.25] [PMID: 19536127]
[19]
Gianatti, E.J.; Grossmann, M. Testosterone deficiency in men with Type 2 diabetes: Pathophysiology and treatment. Diabet. Med. J. Br. Diabet. Assoc., 2020, 37(2), 174-186.
[http://dx.doi.org/10.1111/dme.13977]
[20]
Pivonello, R.; Menafra, D.; Riccio, E.; Garifalos, F.; Mazzella, M.; de Angelis, C.; Colao, A. metabolic disorders and male hypogonadotropic hypogonadism. Front. Endocrinol., 2019, 10, 345.
[http://dx.doi.org/10.3389/fendo.2019.00345] [PMID: 31402895]
[21]
Dudek, P.; Kozakowski, J. Zgliczyński, W. Late-onset hypogonadism. Menopause Rev, 2017, 16(2), 66-69.
[http://dx.doi.org/10.5114/pm.2017.68595]
[22]
Diab, N.; Daya, N.R.; Juraschek, S.P.; Martin, S.S.; McEvoy, J.W.; Schultheiß, U.T. Prevalence and risk factors of thyroid dysfunction in older adults in the community. Sci. Rep., 2019, 9, 13156.
[http://dx.doi.org/10.1038/s41598-019-49540-z]
[23]
Omori, K.; Nomura, K.; Shimizu, S.; Omori, N.; Takano, K. Risk factors for adrenal crisis in patients with adrenal insufficiency. Endocr. J., 2003, 50(6), 745-752.
[http://dx.doi.org/10.1507/endocrj.50.745]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy